AbbVie Inc.
—- Market cap
- —
- Debt
- +$65.00B
- Cash
- −$5.23B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ABBV stock price vs PNR: inconclusive — current versus $33.72 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PNR's multiple
Implied fair value · at ABBV's multiple
Needs ABBV P/E.
Snapshot Sep 11, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
AbbVie Inc. · implied price per share
Bear
$74.44
Base
$92.88
Bull
$117.70
Pentair plc · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Pfizer Inc.
ABBV vs PFE
Johnson & Johnson
ABBV vs JNJ
Merck & Co., Inc.
ABBV vs MRK
Eli Lilly and Company
ABBV vs LLY
Amgen Inc.
ABBV vs AMGN
Gilead Sciences, Inc.
ABBV vs GILD
WATTS WATER TECHNOLOGIES INC
ABBV vs WTS
SMITH A O CORP
ABBV vs AOS
Ingersoll Rand Inc.
ABBV vs IR
Xylem Inc.
ABBV vs XYL
EMERSON ELECTRIC CO
ABBV vs EMR
IDEX CORP /DE/
ABBV vs IEX
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ABBV's premium multiples and current price can be sustained by continued above-PNR execution and remains within its historical trading band, then avoid treating it as a valuation bargain; based on the provided data, the stronger move is to be cautious or underweight ABBV versus PNR because ABBV already trades well above PNR-implied and DCF values.
ABBV's current price of $261.11 is far above PNR-implied price range of $46.35-$127.01 and also above the DCF range of $82.23-$111.26, implying a substantial valuation premium. The gap is driven by ABBV trading at 110.6x P/E, 7.5x P/S, and 25.3x EV/EBITDA versus PNR's 19.4x, 3.0x, and 14.0x, respectively.
Supporting Metrics